Potential antipsoriatic effect of chondroitin sulfate through inhibition of NF-κB and STAT3 in human keratinocytes

Pharmacological Research

Volumn 70, Issue 1, 2013, Pages 20-26

  Andrés, Rosa M ^a,b   Payá, Miguel ^a,b   Montesinos, M Carmen ^a,b   Ubeda, Amalia ^a,b   Navalón, Pedro ^c   Herrero, Marta ^d   Vergés, Josep ^d   Terencio, M Carmen ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Centre of Molecular Recognition and Technological Development (IDM)   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d BIOIBERICA SA   (Spain)

Author keywords

Chondroitin sulfate; Human keratinocytes; NF B; Psoriasis; STAT3

Indexed keywords

CHONDROITIN SULFATE; CUTANEOUS T CELL ATTRACTING CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIPSORIATIC ACTIVITY; ARTICLE; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CELLS, CULTURED; CHONDROITIN SULFATES; DERMOSCOPY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; KERATINOCYTES; MICROSCOPY, FLUORESCENCE; NF-KAPPA B; PRIMARY CELL CULTURE; PROTEIN BINDING; PSORIASIS; STAT3 TRANSCRIPTION FACTOR;

EID: 84875127563     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2012.12.004     Document Type: Article

References (48)

1. G.K. Perera, P. Di Meglio, and F.O. Nestle Psoriasis Annual Review of Pathology 7 2012 385 422
2. V. Quivy, and C. Van Lint Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation Biochemical Pharmacology 68 2004 1221 1229
3. T. Banno, A. Gazel, and M. Blumenberg Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling Journal of Biological Chemistry 279 2004 32633 32642
4. A. Wullaert, M.C. Bonnet, and M. Pasparakis NF-kappaB in the regulation of epithelial homeostasis and inflammation Cell Research 21 2011 146 158
5. P.F. Lizzul, A. Aphale, R. Malaviya, Y. Sun, S. Masud, and V. Dombrovskiy Differential expression of phosphorylated NF-kappaB/rela in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept Journal of Investigative Dermatology 124 2005 1275 1283
6. A.T. Pietrzak, A. Zalewska, G. Chodorowska, D. Krasowska, A. Michalak-Stoma, and P. Nockowski Cytokines and anticytokines in psoriasis Clinica Chimica Acta 394 2008 7 21
7. J.L. Riis, C. Johansen, C. Vestergaard, K. Otkjaer, K. Kragballe, and L. Iversen Ccl27 expression is regulated by both p38 MAPK and ikkbeta signalling pathways Cytokine 56 2011 699 707
8. B. Homey, H. Alenius, A. Muller, H. Soto, E.P. Bowman, and W. Yuan Ccl27-ccr10 interactions regulate t cell-mediated skin inflammation Nature Medicine 8 2002 157 165
9. C. Vestergaard, C. Johansen, K. Otkjaer, M. Deleuran, and L. Iversen Tumor necrosis factor-alpha-induced ctack/ccl27 (cutaneous t-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor kappaB Cytokine 29 2005 49 55
10. A. Campanati, G. Goteri, O. Simonetti, G. Ganzetti, K. Giuliodori, and D. Stramazzotti Ctack/ccl27 expression in psoriatic skin and its modification after administration of etanercept British Journal of Dermatology 157 2007 1155 1160
11. K. Wolk, H.S. Haugen, W. Xu, E. Witte, K. Waggie, and M. Anderson IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not Journal of Molecular Medicine (Berlin) 87 2009 523 536
12. R.M. Grossman, J. Krueger, D. Yourish, A. Granelli-Piperno, D.P. Murphy, and L.T. May Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes Proceedings of the National Academy of Sciences of the United States of America 86 1989 6367 6371
13. S.M. Sa, P.A. Valdez, J. Wu, K. Jung, F. Zhong, and L. Hall The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis Journal of Immunology 178 2007 2229 2240
14. S. Sano, K.S. Chan, S. Carbajal, J. Clifford, M. Peavey, and K. Kiguchi Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model Nature Medicine 11 2005 43 49
15. B.B. Aggarwal, A.B. Kunnumakkara, K.B. Harikumar, S.R. Gupta, S.T. Tharakan, and C. Koca Signal transducer and activator of transcription-3, inflammation, and cancer: How intimate is the relationship? Annals of the New York Academy of Sciences 1171 2009 59 76
16. T. Hardingham Chondroitin sulfate and joint disease Osteoarthritis and Cartilage 6 Suppl. A 1998 3 5
17. P. du Souich, A.G. Garcia, J. Verges, and E. Montell Immunomodulatory and anti-inflammatory effects of chondroitin sulphate Journal of Cellular and Molecular Medicine 13 2009 1451 1463
18. L.M. Wildi, J.P. Raynauld, J. Martel-Pelletier, A. Beaulieu, L. Bessette, and F. Morin Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI Annals of the Rheumatic Diseases 70 2011 982 989
19. D. Uebelhart Clinical review of chondroitin sulfate in osteoarthritis Osteoarthritis and Cartilage 16 Suppl. 3 2008 S19 S21
20. K.M. Jordan, N.K. Arden, M. Doherty, B. Bannwarth, J.W. Bijlsma, and P. Dieppe Eular recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (escisit) Annals of the Rheumatic Diseases 62 2003 1145 1155
21. J. Verges, E. Montell, M. Herrero, C. Perna, J. Cuevas, and M. Perez Clinical and histopathological improvement of psoriasis with oral chondroitin sulfate: a serendipitous finding Dermatology Online Journal 11 2005 31
22. I. Moller, M. Perez, J. Monfort, P. Benito, J. Cuevas, and C. Perna Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study Osteoarthritis and Cartilage 18 Suppl. 1 2010 S32 S40
23. S.T. Boyce, and R.G. Ham Cultivation, frozen storage, and clonal growth of normal human epidermal keratinocytes in serum-free media Methods in Cell Science 9 1985 83 93
24. E. Borenfreund, H. Babich, and N. Martin-Alguacil Comparisons of two in vitro cytotoxicity assays-the neutral red (NR) and tetrazolium MTT tests Toxicol In Vitro 2 1988 1 6
25. M.D. Guerrero, M. Aquino, I. Bruno, M.C. Terencio, M. Paya, and R. Riccio Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prostaglandin e synthase-1 expression Journal of Medicinal Chemistry 50 2007 2176 2184
26. C. Cataisson, A.J. Pearson, S. Torgerson, S.A. Nedospasov, and S.H. Yuspa Protein kinase c alpha-mediated chemotaxis of neutrophils requires NF-kappa B activity but is independent of TNF alpha signaling in mouse skin in vivo Journal of Immunology 174 2005 1686 1692
27. C. Jomphe, M. Gabriac, T.M. Hale, L. Heroux, L.E. Trudeau, and D. Deblois Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes Basic and Clinical Pharmacology and Toxicology 102 2008 59 65
28. K. Miyoshi, M. Takaishi, K. Nakajima, M. Ikeda, T. Kanda, and M. Tarutani Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with sta-21, a stat3 inhibitor Journal of Investigative Dermatology 131 2011 108 117
29. N. Canas, R. Gorina, A.M. Planas, J. Verges, E. Montell, and A.G. Garcia Chondroitin sulfate inhibits lipopolysaccharide-induced inflammation in rat astrocytes by preventing nuclear factor kappa B activation Neuroscience 167 2010 872 879
30. G.M. Campo, A. Avenoso, S. Campo, A. D'Ascola, P. Traina, and A. Calatroni Chondroitin-4-sulphate inhibits NF-kb translocation and caspase activation in collagen-induced arthritis in mice Osteoarthritis and Cartilage 16 2008 1474 1483
31. P.P. Tak, and G.S. Firestein NF-kappaB. A key role in inflammatory diseases Journal of Clinical Investigation 107 2001 7 11
32. A.B. Gottlieb, F. Chamian, S. Masud, I. Cardinale, M.V. Abello, and M.A. Lowes TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques Journal of Immunology 175 2005 2721 2729
33. C.X. Xu, H. Jin, Y.S. Chung, J.Y. Shin, K.H. Lee, and G.R. Beck Jr. Chondroitin sulfate extracted from Ascidian tunic inhibits phorbol ester-induced expression of inflammatory factors vcam-1 and cox-2 by blocking NF-kappaB activation in mouse skin Journal of Agricultural and Food Chemistry 56 2008 9667 9675
34. F. Wan, and M.J. Lenardo The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives Cell Research 20 2010 24 33
35. C. Johansen, E. Flindt, K. Kragballe, J. Henningsen, M. Westergaard, and K. Kristiansen Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin Journal of Investigative Dermatology 124 2005 1284 1292
36. S. Sano, K.S. Chan, and J. DiGiovanni Impact of stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases Journal of Dermatological Science 50 2008 1 14
37. N.C. Reich Stat3 revs up the powerhouse Science Signaling 2 2009 pe61
38. V. Cimica, H.C. Chen, J.K. Iyer, and N.C. Reich Dynamics of the stat3 transcription factor: nuclear import dependent on ran and importin-beta1 PLoS One 6 2011 e20188
39. L. Liu, K.M. McBride, and N.C. Reich Stat3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3 Proceedings of the National Academy of Sciences of the United States of America 102 2005 8150 8155
40. N. Volpi Oral bioavailability of chondroitin sulfate (condrosulf) and its constituents in healthy male volunteers Osteoarthritis and Cartilage 10 2002 768 777
41. N. Volpi Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers Osteoarthritis and Cartilage 11 2003 433 441
42. T.F. Smetsers, E.M. van de Westerlo, G.B. ten Dam, I.M. Overes, J. Schalkwijk, and G.N. van Muijen Human single-chain antibodies reactive with native chondroitin sulfate detect chondroitin sulfate alterations in melanoma and psoriasis Journal of Investigative Dermatology 122 2004 707 716
43. S. Wandel, P. Juni, B. Tendal, E. Nuesch, P.M. Villiger, and N.J. Welton Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis British Medical Journal 341 2010 c4675
44. ® Open Rheumatology Journal 6 2012 183 189
45. M.C. Hochberg Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration Osteoarthritis and Cartilage 18 Suppl. 1 2010 S28 S31
46. D. Uebelhart, M. Malaise, R. Marcolongo, F. de Vathaire, M. Piperno, and E. Mailleux Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo Osteoarthritis and Cartilage 12 2004 269 276
47. D.O. Clegg, D.J. Reda, C.L. Harris, M.A. Klein, J.R. O'Dell, and M.M. Hooper Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis New England Journal of Medicine 354 2006 795 808
48. S.C. Williams New biologic drugs get under the skin of psoriasis Nature Medicine 18 2012 638